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Abstract: Hyperprolactinaemia is one of the most common problems in clinical endocrinology.
It relates with various aetiologies (physiological, pharmacological, pathological), the clarification
of which requires careful history taking and clinical assessment. Analytical issues (presence of
macroprolactin or of the hook effect) need to be taken into account when interpreting the prolactin
values. Medications and sellar/parasellar masses (prolactin secreting or acting through “stalk effect”)
are the most common causes of pathological hyperprolactinaemia. Hypogonadism and galactorrhoea
are well-recognized manifestations of prolactin excess, although its implications on bone health,
metabolism and immune system are also expanding. Treatment mainly aims at restoration and
maintenance of normal gonadal function/fertility, and prevention of osteoporosis; further specific
management strategies depend on the underlying cause. In this review, we provide an update on the
diagnostic and management approaches for the patient with hyperprolactinaemia and on the current
data looking at the impact of high prolactin on metabolism, cardiovascular and immune systems.
Keywords: prolactin; hyperprolactinaemia; prolactinoma; antipsychotics; hypogonadism; dopamine
agonists
1. Introduction
Prolactin (PRL) was first discovered between the late 1920s and early 1930s after different authors
independently demonstrated lobular-alveolar development and lactation in rabbits after injection of
an anterior pituitary extracts [1,2]. In 1933, the “pro-lactin” hormone was purified from animals and
was given its name by Riddle et al. [3]. It was first separated from growth hormone (GH) in human
pituitary glands by Friesen et al. in 1970 [4], as prior to this, radioimmunoassay differentiating PRL
from GH was not available [1,2,5–7]. Though initially recognized for its lactogenic action, PRL is now
understood to act at many different tissues producing a diverse range of biological functions [8]. PRL
belongs to the PRL/GH/placental lactogen family, the members of which share common structural,
functional, and binding properties, and arise from a common ancestral gene [2,8].
Secretion of PRL by the pituitary gland has a circadian rhythm with higher levels during sleep and
lower during wakefulness [6]. Increased concentrations are also seen during ovulation [9]. Synthesis
and secretion of PRL is regulated through both inhibiting and releasing factors [8]. PRL inhibiting
factors include dopamine, gamma-aminobutyric acid (GABA), and somatostatin [8]. Dopamine is the
main inhibitory factor involved in PRL regulation and acts through binding to D2 and D4 receptors in
the pituitary lactotrophs. This results in down-regulation of PRL gene expression, reduced secretion
of PRL, and decreased lactotroph proliferation [10]. Several hormones and neuropeptides have been
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suggested to promote PRL release including thyrotropin-releasing hormone (TRH), endogenous
opioids, oxytocin, serotonin, vasopressin, vasoactive intestinal polypeptide (VIP), neurotensin, galanin,
and salsolinol [8,11]. Nonetheless, PRL is unique from other pituitary hormones in that a physiological
“PRL-releasing factor” has not been as yet identified [11]. PRL is also produced in extra-pituitary sites
including the ovaries, mammary glands and endometrium, prostate, lymphocytes and hematopoietic
cells, skin, adipose tissue, thymus and lymphatic system, endothelium, and the brain [12,13]. It is
structurally identical to pituitary PRL and binds to the same receptor [13]. Its regulation is site specific
and differs from that of pituitary PRL [13].
The PRL receptor (PRL-R) is a single membrane-bound protein of the cytokine receptor superfamily
and is structurally and functionally similar to the GH receptor [8]. It is expressed in the pituitary and in
many other tissues including the mammary gland, endometrium, ovaries, heart, lung, thymus, spleen,
liver, pancreas, kidney, adrenal gland, skeletal muscle, brain, skin and osteoblasts [8,13].
The lactotrophic and reproductive actions of PRL are well established, and in recent years,
there has been enhanced understanding of the many other biological effects of extra pituitary PRL in
humans [9,13]. In women, it is involved in follicular development and maintenance of the corpus luteum,
and also acts on the mammary gland to induce and maintain lactation [14]. In the adrenals, it stimulates
the secretion of androgens [including dehydroepiandrosterone (DHEA)], cortisol, and aldosterone [9].
PRL has been implicated in the stress-induced activation of the hypothalamic-pituitary-adrenal (HPA)
axis [9,13,15]. It increases secretion of ACTH, induces adrenal hypertrophy and storage of cholesterol
esters, and stimulates cortisol production [9,15]. PRL produced from lymphocytes and hematopoietic
cells has been postulated to be involved in the immune response to stress [8,9,13,15]; its action appears
to be dose-related, with immune stimulation at modest and inhibition at high levels [9]. It has varying
effects on bone during development and reproduction; in the foetus, it promotes bone growth and
mineralization, whereas during pregnancy, it contributes to the accelerated bone resorption providing
micronutrients to the foetus [16]. It has vasoconstrictive action and a role in hypertension and
pre-eclampsia has been postulated [14]. Finally, it is thought to be involved in osmoregulation by
increasing water and salt absorption in the bowel and reducing renal Na+ and K+ excretion [9].
Further possible actions of extra-pituitary PRL have been explored in animal studies. Knock-out
PRL-R male mice have infertility proposing a role of PRL in spermatogenesis [10]. Animal models
have also suggested metabolic actions including stimulating insulin release, beta-cell proliferation,
and adipogenesis [10], whereas in the central nervous system, PRL promotes remyelination [9,17].
2. Causes and Mechanisms of Hyperprolactinaemia
The aetiology of hyperprolactinaemia is broad and can be divided into physiological, pathological,
and pharmacological causes (Table 1) acting though a number of different mechanisms [6].
Table 1. Main Causes of Hyperprolactinaemia.
Physiological Pathological Pharmacological
• Ovulation
• Pregnancy
• Breastfeeding
• Stress
• Exercise
• Nipple stimulation or
chest wall injury
• Prolactin-secreting pituitary adenoma
• “Stalk-effect” from sellar/parasellar lesions
• Renal Failure
• Liver Cirrhosis
• Primary hypothyroidism
• Polycystic Ovarian Syndrome (PCOS)
• Seizures
• Antipsychotics/neuroleptics
• Antidepressants
• Antiemetics
• Opioids
• Antihypertensives
2.1. Physiological Causes
2.1.1. Endogenous Oestrogens
Oestrogens enhance PRL secretion via different proposed mechanisms including regulation
of PRL gene expression, downregulation of dopamine receptor expression, and stimulation of
J. Clin. Med. 2019, 8, 2203 3 of 24
lactotroph cell hyperplasia [8,11]. Accordingly, PRL levels are influenced by the menstrual cycle,
menopause, and pregnancy, and any high oestrogen state (e.g., pregnancy) is a potential cause
hyperprolactinaemia [18,19]. Tanner et al. assessed PRL concentrations in 6540 subjects including men,
non-pregnant women at different phases of the menstrual cycle, and post-menopausal women [18].
Pre-menopausal women had significantly higher values compared with post-menopausal ones and
men [18]. Furthermore, PRL was significantly higher during ovulation, leading the authors to advocate
for the use of specific reference intervals according to the phase of menstrual cycle, or measurement of
PRL in the early follicular phase [18].
Hyperprolactinaemia is a well-established finding during normal pregnancy [19]. In a study of
994 women, non-pregnant, pregnant, or post-partum, Hu et al. [19] found PRL levels progressively
increasing across the three trimesters of pregnancy; 29.19 to 168.44 µg/L for the first trimester, 67.3 to
251.43 µg/L for the second, and 192.1 to 457.48 µg/L for the third one.
Increases in PRL can occur with use of oral contraceptives containing high doses of oestrogen
(35 mcg) [20] but this has not been shown with modern contraceptives with lower amounts of
oestrogen [19,21].
2.1.2. Breastfeeding
Suckling during nursing is a strong physiologic stimulus for PRL secretion [8] possibly by releasing
the lactotrophs from the tonic inhibition of dopamine [8,22]. TRH, vasopressin, oxytocin, and salsolinol
have also been proposed as factors involved in the suckling-induced PRL release [8,22].
2.1.3. Stress
Hyperprolactinaemia with values usually up to 100 µg/L may be observed as a response to
stress [6,15,23] but the responsible mechanism has not been fully elucidated. It has been postulated
that stress-induced changes in dopamine and serotonin may affect PRL release contributing to
hyperprolactinaemia in this setting [15].
2.1.4. Exercise
Exercise increases PRL in a magnitude proportional to the intensity and duration of the activity [24,25].
Elevation in PRL has been observed following both aerobic and anaerobic exercise but it is greatest
in high-intensity anaerobic exercise such as interval training [24]. The peak PRL is thought to occur
following exercise [24], and, therefore, it is suggested to avoid vigorous exercise for at least 30 min before
blood sampling for PRL measurement [26]. The mechanism of exercise induced-hyperprolactinaemia
has not been not fully elucidated.
2.1.5. Chest Wall Injury
Different processes causing chest wall irritation such as burns, herpes zoster, or injury have
been associated with hyperprolactinaemia [25]. This is thought to take place via a neural mechanism
interfering with dopamine transmission, as that occurs with suckling [8,22]. Despite the finding
that lactation and nipple stimulation can increase PRL [8], breast examination, breast ultrasound,
or mammography do not appear to cause hyperprolactinaemia [27–29].
2.2. Pathological Causes
2.2.1. Prolactin-Secreting Pituitary Tumours
The most common pituitary cause of hyperprolactinaemia is the presence of prolactinoma. This
is the most frequent subtype of pituitary adenoma (accounting for 57% of all pituitary adenomas),
and presents more commonly in females with a peak prevalence in women aged 16 to 48 years [30].
Prolactinomas are classified by their size, with microprolactinomas measuring <1 cm and
macroprolactinomas ≥1 cm (giant ones measure >4 cm) [25,31]. In general, the degree of
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hyperprolactinaemia correlates with prolactinoma size, however, there are some important caveats to
this which will be addressed in the Diagnosis section below. For microprolactinomas, PRL is usually
100 to 200 µg/L, however, outliers exist; in the Brazilian Multicenter Study on Hyperprolactinaemia
which included 444 patients with microprolactinoma, mean PRL was 165 µg/L but ranged from 32 to
525 µg/L [32]. Hyperprolactinaemia is also seen in adenomas co-secreting GH and PRL [33,34].
Based on the 2017 WHO classification of pituitary adenomas, morphological variants of the
lactotroph adenomas are the sparsely granulated, the densely granulated, and the acidophil stem cell
adenoma which also expresses GH [35]. PRL expression is also seen by immunohistochemistry in
pluri-hormonal Pit-1 adenomas, mammosomatotroph adenomas, and mixed somatotroph-lactotroph
adenomas [35].
Prolactin secreting adenomas can be part of genetic syndromes, such as multiple endocrine
neoplasia type 1 (MEN1) or type 4 (MEN4), familial isolated pituitary adenoma (FIPA) or Carney
complex [36]. MEN1 is an autosomal dominant condition usually due to loss of heterozygosity of
the MEN1 gene which encodes the menin protein [36]. Clinical features of MEN1 include primary
hyperparathyroidism, pituitary adenomas, and pancreatic neuroendocrine tumours [36,37]. Although
less than 3% of pituitary adenomas are associated with MEN1, they are present in 30–40% patients
with this syndrome [36,37] with prolactinoma being the most common subtype [36–38]. Inactivating
germline mutations of the aryl hydrocarbon receptor interacting protein (AIP) gene are found in 20% of
families with FIPA [39]. Although AIP mutations are usually associated with GH-secreting adenomas,
they can also be detected in patients with prolactinoma [39]. Carney complex is an autosomal dominant
condition characterized by spotty skin pigmentation, myxomas, and multiple endocrine hyperfunction;
it is most commonly caused by an inactivating germline mutation in the PRKAR1A gene and the
protein it encodes is a type 1A regulatory subunit of protein kinase A [36]. Pituitary adenomas occur in
10 to 20% of patients with Carney complex, most are GH secreting tumours but some of them co-secrete
GH and PRL [36,40].
2.2.2. “Stalk-Effect”
Any lesion leading to interruption of the dopaminergic pathways due to compression of the
pituitary stalk and portal vessels can lead to hyperprolactinaemia through the “stalk effect” [including
pituitary adenomas with the most common cause in this setting being the non-functioning pituitary
adenomas (NFA); parasellar tumours (such as Rathke’s cleft cyst, craniopharyngioma, meningioma
or germinoma); metastatic pituitary disease, infiltrative/inflammatory diseases (such as lymphocytic
hypophysitis, Langerhans cell histiocytosis, and sarcoidosis)] [6,25,41]. Stalk compression from NFA or
other parasellar tumours is typically associated with PRL levels <100µg/L [42,43]. Hyperprolactinaemia
has also been reported in 7 to 10% of patients with primary empty sella syndrome attributed to
compression of the pituitary gland against the sellar walls causing stretching of the pituitary stalk [44].
2.2.3. Renal Failure
Hyperprolactinaemia is common in patients with renal disease and is recognized as a cause
of hypogonadism and sexual dysfunction in these patients [25,45]. PRL usually ranges between 30
and 108 µg/L, although rarely, much higher concentrations exceeding 600 µg/L may be observed [45].
Increased PRL secretion and decreased PRL clearance are both thought to contribute [25,45].
Hyperprolactinaemia resolves following successful renal transplantation [25].
2.2.4. Liver Cirrhosis
Hyperprolactinaemia is common amongst patients with cirrhosis with levels less than 100 µg/L.
Its degree correlates with the severity of liver disease [46]. The mechanism is thought to be secondary
to decreased dopamine-mediated PRL inhibition, as well as increased circulating oestrogen levels [46].
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2.2.5. Primary Hypothyroidism
It has been suggested that approximately 40% of cases of primary hypothyroidism are associated
with hyperprolactinaemia [47,48] caused by stimulation of lactotroph cells from the increased TRH
levels [9]. Its magnitude correlates with the degree of TSH elevation [47]. Hyperprolactinaemia is
typically mild with values <100 µg/L [47,48]. A further mechanism of hyperprolactinaemia secondary
to untreated primary hypothyroidism is thyrotroph hyperplasia, which can mimic a pituitary adenoma
and induce hyperprolactinaemia via the “stalk effect” [25,49].
2.2.6. Polycystic Ovarian Syndrome
Hyperprolactinaemia has been reported in 7 to 52% of women with polycystic ovarian syndrome
(PCOS) [50,51]. Its pathogenesis has not been elucidated; oestrogen-mediated stimulation of lactotrophs
and relative dopamine deficiency have been proposed [50,51]. Given the presence of PRL receptors in
the adrenal gland [8], it has also been postulated that hyperprolactinaemia stimulates adrenal androgen
production contributing to the hyperandrogenism of PCOS [51]. It should be noted that whether
hyperprolactinaemia is truly a clinical feature of PCOS remains controversial. A case-control study of
82 women with PCOS showed no difference in the prevalence of hyperprolactinaemia compared to
women with insulin resistance, and notably, all cases of hyperprolactinaemia in the women with PCOS
were finally attributed to a prolactinoma or medication use [52].
2.2.7. Seizures
Hyperprolactinaemia following seizures is transient with peak levels 10 to 20 min post-seizure
and resolution within 2 to 6 h [53]. It has been proposed that this occurs due to propagation of epileptic
activity from the temporal lobe to the hypothalamo-pituitary axis [54]. It is most common following
generalized tonic-clonic seizures and can also be seen after alcohol withdrawal seizures or complex
partial seizures; it is rare following simple partial or psychogenic non-epileptic seizures [53]. PRL is,
therefore, a potentially useful biomarker in differentiating epileptic seizures from non-epileptic ones
but the sensitivity and specificity of this are highly variable across different series [53].
2.3. Pharmacological
A number of drugs can alter PRL homeostasis leading to hyperprolactinaemia via different mechanisms.
The most common culprit medications are antipsychotics/neuroleptics and antidepressants [6,55] and the
main mechanisms involve reduction in dopamine transmission and increase in serotonin transmission
(with the latter leading to augmentation of PRL releasing factors, like oxytocin and VIP) [55,56].
The prevalence of hyperprolactinaemia amongst different classes of medications is shown in Table 2.
Table 2. Prevalence of hyperprolactinaemia (HPRL) amongst different medications [57,58].
Drug
Class
No Significant
HPRL
HPRL in
<25% of Patients
HPRL in
25–50% of Patients
HPRL in
>50% of Patients
Typical
antipsychotics
• Loxapine
• Pimozide
• Butyrophenone
• Phenothiazines
• Thioxanthenes
Atypical
antipsychotics
• Aripiprazole
• Clozapine
• Ziprasidone
• Olanzapine
• Quetiapine
• Amisulpride
• Risperidone
• Sultopride
• Sulpiride
• Tiapride
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Table 2. Cont.
Drug
Class
No Significant
HPRL
HPRL in
<25% of Patients
HPRL in
25–50% of Patients
HPRL in
>50% of Patients
Tricyclic
antidepressants • Nortriptyline
• Amitriptyline
• Amoxapine
• Clomipramine
• Desipramine
• Doxepin
• Imipramine
• Maprotiline
• Trimipramine
• Clomipramine
Monoamine oxidase
inhibitors
• Clorgiline
• Pargyline
Antiemetics
• Alizapride
• Domperidone
• Metoclopramide
• Metopimazine
Antihypertensives • Methyldopa
• Reserpine • Verapamil
2.3.1. Antipsychotics
Antipsychotics are typically divided into those with PRL-rising and PRL-sparing potential [56].
Possible explanations for these differences include variations in the speed of dissociation from
the D2R, ability to cross the blood-brain barrier, presence of D2R polymorphisms, and degree of
serotonergic inhibition [55,56,59]. First generation antipsychotics are typically associated with more
severe hyperprolactinaemia (two to three times the upper limit of normal) [55]. Second generation
antipsychotics have lower D2R affinity and stronger 5HT2A receptor blockage leading to milder PRL
elevations [55]. Exceptions to this are risperidone, paliperidone and amisulpride, all second-generation
antipsychotics that can cause significant hyperprolactinaemia [55,56]. Both oral and depot formulations
of risperidone and paliperidone increase PRL in a dose dependent manner. Amisulpride is thought to
have the greatest potential for hyperprolactinaemia of all antipsychotics; these effects occur independent
of dose and can resolve rapidly after discontinuation of the drug [55]. Aripiprazole and quetiapine
show the lowest possibility for hyperprolactinaemia [55,56].
The PRL raising potential of commonly used first and second-generation antipsychotics is shown
in Table 3.
Table 3. Hyperprolactinaemia (HPRL) amongst different antipsychotics.
Drug Mild HPRL (<50 µg/L)(% of Patients)
Moderate HPRL (50–100 µg/L)
(% of Patients)
Severe HPRL (>100 µg/L)
(% of Patients)
Aripiprazole * √ (0.36) √ (2.55)
Olanzapine * √ (26.66) √ (11) √ (2)
Quetiapine * √ (9.09) √ (9) √ (5)
Depot Risperidone * √ (30.76) √ (23.07) √ (30.79)
Oral Risperidone * √ (14.58) √ (43.75) √ (22.91)
Oral Paliperidone * √ (18.18) √ (45.45) √ (18.18)
Depot Paliperidone * √ (13.33) √ (40) √ (40)
Phenothiazines ** √
Amisulpride *** √ (45%)
Sulpiride ∞ √
Haloperidol † √ √
* [56], ** [60], *** [61], ∞ [62], † [63].
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2.3.2. Antidepressants
Different classes of antidepressants, including monoamine oxidase inhibitors, tricyclic antidepressants,
and selective serotonin reuptake inhibitors (SSRIs) induce hyperprolactinaemia mainly via serotonergic
pathways [55,59]. This is typically mild and it is rarely symptomatic [59].
2.3.3. Antiemetics
The antiemetics domperidone and metoclopramide antagonize D2R and can acutely induce
hyperprolactinaemia [55,59]. These effects can be harnessed for increasing breast milk production for
breastfeeding [64].
2.3.4. Opioids
Opioids can cause hyperprolactinaemia mediated by µ-, κ- and δ-opioid receptors in the
hypothalamus [65]. Acute oral or iv opioid administration can induce hyperprolactinaemia in
men and post-menopausal women, while the findings after chronic opioid use have been mixed [65].
High PRL has been found in individuals with opioid addiction, with opium smoking and on oral
opioids for chronic pain, but not with intrathecal morphine or opioid maintenance therapy with
buprenorphine or methadone [65].
2.3.5. Antihypertensives
Verapamil is a non-dihydropyridine calcium channel blocker of the phenylalkylamine class [66].
This specific class of calcium channels blocker causes hyperprolactinaemia due to suppression of
tuberoinfundibular dopamine; this is not seen with the other commonly used non-dihydropyridine
agents diltiazem and nifedipine [67]. Methyldopa is a competitive inhibitor of the enzyme DOPA
decarboxylase and causes hyperprolactinaemia through inhibition of dopamine synthesis [58].
Reserpine is an alkaloid used for treatment of hypertension and psychosis; it reduces dopamine
transmission by blockade of vesicular monoamine transporter type 2 in monoamine neurons [68].
3. Clinical Manifestations
The clinical manifestations of hyperprolactinaemia mainly relate with the reproductive
system [25,43]. The patients may also have other signs and symptoms depending on the aetiology
of the PRL excess (e.g., mass effects, in case of a pituitary tumour (headaches, visual disturbances,
hypopituitarism)).
3.1. Reproductive Manifestations
3.1.1. Women
Hyperprolactinaemia suppresses GnRH (via reduction of kisspeptin in the hypothalamic arcuate
and periventricular neurons) leading to a decrease in LH pulse amplitude and frequency [43]. It also
decreases ovarian oestrogen and progesterone production [43]. These result in menstrual irregularities
(amenorrhoea or oligomenorrhoea), infertility, decreased libido and galactorrhoea [25]. Galactorrhoea
(spontaneous or provoked) is a common manifestation in pre-menopausal females (up to 90%), but
occurs less often in post-menopausal ones as the mammary glands are not primed with oestrogen and
progesterone [69].
Hyperandrogenism may be also a manifestation of hyperprolactinaemia due to stimulation of adrenal
androgen production [51,70–72]. In a prospective study including 101 medically and 22 surgically treated
patients with prolactinoma and normal cortisol reserve, decreases in the adrenal steroid DHEA-S
paralleled PRL reduction after treatment with dopamine agonist or surgery [72]. However, this study
did not report on clinical symptoms of hyperandrogenism [72]. It is also unclear whether there is a link
between hyperprolactinaemia and female pattern hair loss [73]. It is possible that PRL exacerbates
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hyperandrogenism in clinically predisposed women, such as those with PCOS [51] but further studies
are needed on this topic.
3.1.2. Men
In males, hyperprolactinaemia causes hypogonadotropic hypogonadism [74] manifesting with
reduced libido, erectile dysfunction, and impaired spermatogenesis [75]. Gynaecomastia (secondary to
hypogonadism) and galactorrhoea occur rarely [75]. Anaemia, decreased energy and muscle mass
may be also present as secondary manifestations of hypogonadism [71,76].
3.2. Bone Manifestations
It is well established that hypogonadotropic hypogonadism has negative impacts on bone
health [77]. Furthermore, in vitro studies have demonstrated that PRL has variable effects on bone
metabolism, depending on its levels. PRL within the physiological range stimulates bone formation,
mild hyperprolactinaemia increases bone resorption, and marked hyperprolactinaemia further increases
bone resorption and inhibits bone formation [77]. This is supported by findings that patients with
prolactinoma have suppressed osteocalcin, high NTX (collagen type I crosslinked N-telopeptide),
and increased RANKL (receptor activator of nuclear factor-kB ligand)/OPG (osteoprotegerin) ratio,
suggesting increased bone resorption and decreased bone formation [77,78]. The relative contribution of
hypogonadotropic hypogonadism and hyperprolactinemia is controversial and it has been hypothesized
that these mechanisms have synergistic effects on bone loss [77]. In vitro and animal studies
have suggested that hyperprolactinaemia directly stimulates bone resorption independently of
hypogonadism [77] but further research on this topic is needed.
Bone loss affects both men and women with prolactinoma, and reduced bone mineral density is
more common in the lumbar spine than in the hip, suggesting that trabecular bone may be damaged
earlier than cortical bone [77,79]. In a case control study, higher rates of vertebral fractures were found
in women with prolactinoma compared with controls [80]. A systematic review and meta-analysis
demonstrated that rates of vertebral fractures were significantly lower in treated vs. untreated men
and women with prolactinoma, independent of gonadal function [81].
4. Diagnostic Approach
4.1. Blood Sampling for PRL
Current guidelines state that serum PRL can be drawn at any time of day [25]. Exercise and nipple
stimulation should be avoided for at least 30 min prior to testing [26].
Typically, normal PRL levels are <20 µg/L in men and <25 µg/L in women [82], however, it
is important to interpret the results according to the assay specific reference ranges [83], and also
considering pre/post-menopausal status. [18,19]. A single PRL value above the upper limit of normal
can be sufficient for confirmation of hyperprolactinaemia, provided blood sampling took place without
excessive venepuncture stress [25]. However, if there is doubt, particularly in cases of mildly elevated
PRL, sampling could be repeated at 15 to 20 min intervals to account for pulsatility [9,25]. Dynamic
tests are not currently used for establishing the diagnosis of hyperprolactinaemia [25].
4.2. Biochemical Interpretation
4.2.1. Macroprolactin
Most circulating PRL (23 kDa) is monomeric, however, serum also contains larger isoforms including
dimeric PRL or big PRL (45 to 60 kDa) and polymeric or big-big PRL (150 to 170 kDa) [25,26]. Big-big
PRL, termed macroprolactin, is mostly complexes of prolactin-IgG, prolactin-IgA, or polymeric
aggregates of highly glycosylated PRL monomers [84]. In most individuals, the majority of
serum PRL (~85%) is monomeric but in others there is preponderance of macroprolactin, referred
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to as macroprolactinaemia [25,26]. The prevalence of macroprolactinaemia amongst cases with
hyperprolactinaemia is reported between 4% and 40% [25,26,85]. Although macroprolactin is not
considered to have significant biological activity, it retains partial or total immunoreactivity with
anti-PRL antibodies used in commercial immunoassays [83–85]. Detection of macroprolactin is
clinically important to avoid incorrect diagnosis and unnecessary investigations [83]. Gel filtration
chromatography is regarded as the “gold standard” technique, however, it is labour-intensive and
expensive [83,84,86]. Polyethylene glycol (PEG) precipitation is the most widely used method, as it is
simple, fast, and cost effective [25,83,84,86]. It involves mixing and incubating the serum with 25% PEG
which is then centrifuged and the precipitating PRL complexes are subsequently quantified [83,84,86].
Recovery of free PRL > 60% of the total is suggestive of monomeric hyperprolactinaemia, whereas
recovery <40% is consistent with macroprolactinaemia [33,86].
Despite the general view that macroprolactin does not have significant biological activity, in recent
years, this has been a matter of debate [83,85]. Thus, it has been proposed that macroprolactin can
dissociate into biologically active monomeric isoforms; nonetheless, studies assessing the biological
activity of macroprolactin in vitro have yielded conflicting results [83,85,86]. Kalsi et al. [87] in a study
of 102 hyperprolactinaemic individuals, found that 68.8% of those with macroprolactinaemia had
reproductive manifestations that could not be otherwise explained. This led the authors to propose
that macroprolactin may have some degree of biological activity [87] but these findings require further
validation. In daily practice, if macroprolactin is not assessed in local hospital laboratories, this can be
evaluated in most reference laboratories upon request.
4.2.2. Hook Effect
Hook effect is another analytical issue important in clinical practice [25,26]. It is encountered
in the presence of excessively high PRL levels (as seen with macro- or giant prolactinomas) which
saturate the antibodies used in the two-site immunoradiometric assay leading to artificially low PRL
values [25,26]. Failure to recognize this effect may result in missing the diagnosis of a prolactinoma
and to incorrect therapeutic decisions [88]. Large pituitary macroadenomas (>3 cm with expected PRL
level >10,000 µg/L) with only mild hyperprolactinaemia should raise suspicion for the hook effect,
and close interaction between clinicians and biochemists is required in this scenario [25,26]. It can be
overcome by repeating the assay on 1:100 serum sample dilutions, or by performing a washout just
after the binding of PRL to the first antibody aiming to eliminate the excessive unbound PRL [25,26].
As many newer PRL assays are no longer susceptible to the hook effect, clinicians should consult with
their local laboratories when querying this issue [25].
4.3. Imaging
The diagnostic work-up of hyperprolactinaemia includes imaging of the sellar area, which is
performed after excluding other common causes of high prolactin (physiological, primary hypothyroidism,
drug-induced). Pituitary MRI (magnetic resonance imaging) enhanced with gadolinium is the gold
standard approach [82].
4.4. Diagnostic Algorithm
In patients on PRL-elevating drugs, PRL should be repeated after withdrawal of medications
for 72 h, if possible [25,56]. However, this approach may not be safe if this treatment is offered for
psychiatric indications [89]. If stopping the drug is not feasible, pituitary MRI is advised to rule out a
sellar/parasellar tumour [25,56]. Due to the challenges in investigating hyperprolactinaemia in such
scenarios, checking baseline PRL levels prior to initiation of antipsychotic medication is recommended
aiming to avoid future unnecessary imaging [56].
The differentiation between a PRL-secreting tumour and a NFA or other sellar/parasellar mass
causing hyperprolactinaemia through “stalk effect” is very important, as these conditions are managed
differently [42]. In prolactinomas, apart from the cystic ones [43], adenoma size generally corresponds
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with PRL levels. Nonetheless, there is no PRL cut-off with perfect diagnostic value differentiating
prolactinoma from other tumours [42]. Karavitaki et al. [42] in a series of 226 histologically proven
NFAs showed that 99% of them had serum PRL of <2000 mU/L (~100 µg/L) suggesting that PRL
above this limit is most likely consistent with a prolactinoma. Rarely, long-standing untreated
primary hypothyroidism can cause significant lactotroph hyperplasia which may mimic a pituitary
adenoma [49]. A proposed diagnostic algorithm for hyperprolactinaemia is shown in Figure 1.
Figure 1. Proposed algorithm for investigating hyperprolactinaemia.
5. Management
The main goals of therapy for hyperprolactinaemia are restoration and maintenance of normal
gonadal function/fertility, and prevention of osteoporosis [74]. Specific management strategies depend
on the underlying aetiology [25,43].
5.1. Prolactinomas
The therapeutic targets in prolactinomas are to normalize PRL, reduce tumour size, resolve
clinical manifestations of hyperprolactinaemia and of mass effects (particularly visual disturbances)
and prevent progression or recurrence of the tumour [25,74].
5.1.1. Conservative Management
Based on current guidelines, patients with microprolactinoma who are asymptomatic or
post-menopausal do not require treatment [25,82,90]. However, some authors advocate treatment in
post-menopausal women due to the postulated negative effects of hyperprolactinaemia on bone health,
weight gain, and insulin resistance [77,91]. Post-menopausal women managed with a conservative
strategy require ongoing surveillance for tumour progression [25,82,90].
5.1.2. Dopamine Agonists
Dopamine agonists (DA) are first line treatment for patients with prolactinoma [25,43,82]. They
induce apoptosis, autophagic cell death and paraptosis of lactotrophs through different molecular
pathways mediated by D2R, leading to reduced prolactin secretion and tumour shrinkage [92].
Available DAs include bromocriptine, cabergoline, and quinagolide [25,43,82]. Bromocriptine is a
semisynthetic ergot derivative with D2R agonist activity and D1R antagonist activity requiring daily
administration due to its short half-life; starting doses are 0.625 to 1.25 mg/day and can be titrated
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to 2.5 to 15 mg/day [25,82,93]. Cabergoline is a D2R selective agonist with longer half-life allowing a
single to twice weekly administration; typical starting doses are 0.25 to 0.5 mg once or twice weekly
with titration to usual doses of 0.5 to 3 mg weekly. [25,82,93]. Quinagolide is a non-ergot derived D2R
agonist with a 22-hour half-life which allows for daily dosing; typical starting doses are 25 mcg daily
usually titrated to 75-150 mcg daily [93]. Current guidelines recommend cabergoline to be used as first
line over bromocriptine due to its superior efficacy (attributed to greater affinity and selectivity for
D2R) and more optimal side effect profile [25,43,82,92]. Improved adherence due to fewer side effects
and more convenient dosing schedule are also further advantages [25,92]. Results from cumulative
studies have demonstrated that DAs result in reduction in tumour size in 20 to 100% (median 62%),
resolution of visual field defects in 33 to 100% (median 67%), resolution of amenorrhea in 40 to 100%
(median 78%), resolution of infertility in 10 to 100% (median 53%), improvement of sexual function in
6 to 100% (median 57%), resolution of galactorrhoea in 33 to 100% (median 86%), and normalization of
PRL in 40 to 100% (median 68%) of the patients [25].
Common side effects of DAs include nausea and/or vomiting and postural hypotension which
can lead to dizziness and syncope, a digital Raynaud-type syndrome, and, more rarely, leg cramps,
flushing, and nasal congestion [94]. High dose DA (as offered in Parkinson’s syndrome) increases the
risk of cardiac valvulopathy [95] but the risk of clinically significant valvulopathy in patients with
prolactinoma is still not clearly established [96]. Most studies on prolactinoma patients do not show an
elevated risk [97–99] but, given the uncertainty around the risk of valvulopathy in this setting, current
guidelines recommend screening echocardiography prior to initiating DA, and thereafter every five
years for patients taking cabergoline less than 2 mg per week or annually for those on more than 2 mg
per week [100].
Rarely, DAs can induce mood changes and psychosis in susceptible patients [101]. More subtle
psychiatric symptoms manifesting as impulse control disorders are also increasingly being recognized [102].
Pituitary apoplexy has been reported during use of DA in a small number of cases [103] and usually
this occurs in patients with macroprolactinoma during the first 1.5 years of treatment [103–105].
Guidelines suggest that withdrawal of DA may be attempted after at least two years of therapy
if PRL has normalized and there is no visible tumour on MRI; remission rates of 26 to 69% have
been observed following discontinuation [25,82]. Withdrawal of DA carries risk of tumour recurrence
or regrowth, particularly in the first year, and ongoing regular surveillance is required [25,82]. DA
withdrawal may also be considered in women once they become post-menopausal [25], however,
prolactinoma regrowth has been observed in this setting, and continued surveillance is required [90].
In case of pregnancy, DA should be discontinued, except in selected patients with macroadenoma
at risk of visual deterioration [25]. Although there is longer experience with use of bromocriptine
than with cabergoline during pregnancy, both have demonstrated safety in this setting [106]. The risk
of prolactinoma growth during pregnancy is <2% for microprolactinomas and around 18% for
macroprolactinomas [25,43,82,106]. If visual deterioration occurs, management options include
reinstitution of DA or surgical debulking [25]. If surgery is to be undertaken, the preferred timing is
during the second trimester [43]. If the pregnancy is at or near term, induction of delivery may also
be considered [25,43]. Remission rates following pregnancy of 10 to 60% (median 27%) have been
reported, and breastfeeding does not appear to increase the risk of tumour growth [43,107,108].
Normalization of PRL and/or tumour shrinkage cannot be achieved with DA treatment in all cases
of prolactinomas [25,109]. Prolactinomas are labelled as DA resistant due to either failure to achieve
normoprolactinaemia and/or failure to achieve 50% reduction in tumour size with maximum tolerated
DA dose (can be up to 30 mg daily for bromocriptine or 12 mg weekly for cabergoline [110,111]) after
at least 6 months of treatment [109]. DA resistance occurs in approximately 20 to 30% of patients on
bromocriptine and around 10% of patients on cabergoline [109]. Male sex, younger age at diagnosis,
tumour invasiveness (particularly in the cavernous sinus) and size >4 cm have been proposed as
clinical factors associated with DA resistance [109,112]. In such cases, switching bromocriptine to
cabergoline is an option, leading to normalization of PRL in 80 to 85% of patients [109]. On the
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other hand, changing cabergoline to bromocriptine is rarely effective [111] but systematic data are
not available. For patients already on cabergoline, dose escalation is another option, as a number of
them (around 15 to 20%) may require higher than the conventional doses of 2 mg per week [25,111].
It is uncommon for a prolactinoma initially responsive to DA to become resistant to this treatment;
if this occurs, adherence to the DA should be confirmed [43,109,111]. Transsphenoidal surgery and
radiotherapy are second and third line management options, respectively, for resistant prolactinomas,
as discussed below [25].
The above strategies are not always successful in overcoming resistance to DA, and, therefore,
alternative medical therapies have been explored [109]. Somatostatin analogues (SSA) alone or in
combination with DA have been proposed as a potential approach, due to expression of all somatostatin
receptor (SSTR) subtypes in prolactinomas [109]. However, results from small case series using
first generation SSA (octreotide and lanreotide) have been conflicting [109]. Second generation SSA
(pasireotide) may confer a theoretical advantage over first generation ones due to greater affinity
for SSTR5, however, successful experience with this agent is limited to two case reports [109]. Due
to the effect of oestrogens on lactotroph proliferation and hyperplasia, case reports and small case
series have explored use of selective oestrogen receptor modulators and aromatase inhibitors for DA
resistant prolactinomas, but the results of these studies are not conclusive [109]. Metformin, tyrosine
kinase inhibitors (EGFR and VEGF inhibitors), and mTOR inhibitors have attracted interest, but clinical
evidence is limited to case reports, necessitating further work on this field [109].
Temozolomide (TMZ) has been used as first line chemotherapeutic agent in lactotroph carcinomas
and aggressive prolactinomas [109]. Lower expression of the DNA repair protein O6-methylguanine-DNA
methyltransferase (MGMT) has been proposed to correlate with TMZ effectiveness and checking for
the MGMT tumour status by immunohistochemistry prior starting treatment is recommended [109].
Response to TMZ within three months of treatment is a predictor of efficacy; discontinuation is advised
if there is radiological progression after that interval [109].
5.1.3. Surgery
Surgery could be considered for prolactinomas where maximum doses of DA are not effective
or tolerated, for those presenting with pituitary apoplexy with visual deterioration, when there
are cystic tumour components compressing the visual pathway, or if cerebrospinal fluid leak
develops [25,43,110,111,113]. Surgery may also be an option for young patients with microprolactinoma,
as this may be a more cost-effective approach compared with lifelong DA therapy [114]. Rates of
post-operative remission are widely variable across the literature, and are reported 38 to 100% for
microprolactinomas and 7 to 80 % for macroprolactinomas [115]; lower rates of remission are described
in tumours with cavernous sinus invasion [111,116]. Higher success rates are seen in the hands of
experienced pituitary surgeons [114]. DA resistant prolactinomas may show improved responsiveness
to these agents following debulking surgery [110,111].
5.1.4. Radiotherapy
Radiotherapy is a third line option for prolactinomas that have failed medical and surgical
management, or for aggressive or malignant ones [25,43,110]. Although it can be effective in controlling
tumour growth, normalization of PRL is reported in only one third of patients, and it may require
up to 20 years for maximal effects to be seen [25,43,111]. Pituitary irradiation is associated with late
adverse effects mainly including hypopituitarism, optic nerve damage, cranial nerve dysfunction, as
well as increased risk of stroke and second brain tumours [25,82,117].
5.2. “Stalk Effect”
Sellar/parasellar tumours leading to hyperprolactinaemia due to the “stalk effect” are usually
managed surgically [118]. In a series of 267 patients with NFA, 72 had hyperprolactinaemia secondary to
“stalk effect” and eight of them had galactorrhoea [119]. At 12 weeks postoperatively, PRL normalized
J. Clin. Med. 2019, 8, 2203 13 of 24
in 92% and all cases of galactorrhoea resolved [119]. In selected cases, there may be clinically significant
hyperprolactinaemia from the “stalk effect” in the absence of other indications for surgery, such as
hormone hypersecretion and visual field compromise. In these patients, hypogonadism should be
treated, and if galactorrhoea is also bothersome, a pragmatic approach is to trial DA [120]. Notably, DA
treatment has been associated with reduction in the rate of residual adenoma enlargement in patients
with NFA who had surgical removal of the tumour [121].
5.3. Other Pathological Causes
Hyperprolactinaemia secondary to primary hypothyroidism should be managed through treatment
of the underlying hypothyroidism with thyroid hormone replacement [25,43].
Hyperprolactinaemia secondary to renal failure has been shown to normalize following successful
renal transplantation [25]. The use of PRL lowering treatment in patients with hyperprolactinaemia
secondary to chronic kidney or liver disease has not been investigated.
5.4. Pharmacological
In hyperprolactinaemia secondary to medication use, the preferred approach is to discontinue the
offending drug [25,43]. However, this strategy may not be safe for patients with psychiatric disorders
on antipsychotics [89]. Although antipsychotic-induced hyperprolactinaemia is common, there is no
consensus on its management due to lack of high quality evidence [89]. Grigg et al. [89] in a systematic
review and critical analysis of published guidelines and literature on this topic proposed that, if possible,
baseline PRL level should be drawn prior to initiating or changing antipsychotic therapy [89]. Patients
with asymptomatic hyperprolactinaemia due to antipsychotics should undergo periodic monitoring
of PRL, as well as regular clinical assessments for relevant manifestations [56,89]. For those with
symptomatic hyperprolactinaemia, a trial of stopping the antipsychotic medication is not recommended
due to risk of exacerbation or relapse of psychiatric symptoms [89]. One option is to decrease the
dose of the antipsychotic but this may result in reduced control of psychiatric symptoms, and may
also be ineffective, as hyperprolactinaemia in this setting is not always dose related [55,89]. Due to
partial agonism at D2R, addition of aripiprazole as an adjunctive therapy has shown to be an effective
strategy in reducing hyperprolactinaemia, however, there is concern that this could lead to a reduction
in the efficacy of the primary antipsychotic or to increased side effects due to polypharmacy [55,59,89].
A further option is initiating hormone replacement therapy with oestrogen (oral contraceptive pill
or hormone replacement therapy depending on whether contraception is required) or testosterone,
as appropriate [89]. Switching antipsychotics to reduce hyperprolactinaemia is a last resort and should
be undertaken with caution only when the psychiatric condition has been stabilized [89]. Use of DA in
this patient population is not currently recommended due risk of worsening psychotic symptoms and
lack of established safety [89]. Management of antipsychotics-induced hyperprolactinaemia should
be undertaken in close collaboration with psychiatry and be individualized based on the potential
benefits and risks of each strategy [89].
6. Hyperprolactinaemia and Metabolic/Cardiovascular Risk
6.1. Metabolic Risk
Animal studies have demonstrated that PRL is implicated in appetite regulation, body weight,
and fat deposition [122]. PRL is involved in the development of pancreatic β-cells and has also been
postulated to have functional importance in the adult pancreas [123]. It may contribute to insulin
resistance and hyperglycaemia through decreasing glucose transporter 4 (GLUT4) expression and
inducing pyruvate dehydrogenase kinase 4, thereby, reducing glucose uptake and oxidation [123].
PRL signalling appears to modulate adipocyte differentiation and impact energy homeostasis and
thermogenesis [123].
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In large population-based studies from China and USA, normal to high-normal PRL levels
(but within the reference range) were related to favourable glucose metabolism profile and low risk
of diabetes mellitus type 2 [124,125]. There is limited data on hyperprolactinaemia and metabolic
parameters. PRL may impact insulin resistance; patients with hyperprolactinaemia have higher insulin,
HOMA-IR, and HOMA-β index levels compared with healthy controls [126]. A correlation between
hyperprolactinaemia and BMI (body mass index) has also been observed in prolactinoma patients
independent of hypogonadism [127].
Several studies have evaluated the effect of treatment of hyperprolactinaemia with DA on
numerous metabolic parameters. DAs reduce triglycerides, fasting glucose, and LDL cholesterol in
individuals with prolactinomas [127]. In contrast, in another study on prolactinoma patients offered DA
demonstrated no change in fasting glucose, although significant decrease of LDL and total cholesterol
were observed [128]. A report of 20 premenopausal women with prolactinoma described significant
decreases in BMI, total cholesterol, and LDL following treatment with DA [129]. Furthermore, in a series
of 61 patients with prolactinoma, significant improvements in lipid profile, insulin resistance, visceral
adiposity, and prevalence of metabolic syndrome following treatment with cabergoline were found [130].
However, it is difficult to discern whether these favourable metabolic effects are directly related to
resolution of hyperprolactinaemia or are due to restoration of gonadal function or a combination
of both. Notably, a study of 32 men with prolactinoma demonstrated significant decreases in the
prevalence of metabolic syndrome after 12 months of treatment with cabergoline only amongst those
with hypogonadism at baseline [131]. Nonetheless, significant improvements in weight, BMI, waist
circumference, lipid profile, and insulin resistance were seen in both hypogonadal and eugonadal
patients, suggesting that PRL may play a direct role in mediating these adverse metabolic effects [131].
6.2. Cardiovascular Risk
It has been proposed that hyperprolactinaemia has cardiovascular actions, either direct or indirectly
through hypogonadism [132,133]. PRL increases sympathetic tone and mediates chronotropic and
vasoconstrictive effects; for this reason, it has been implicated in cardiovascular (CV) risk [132].
In women, PRL >8 µg/L was independently associated with risk of incident hypertension [134].
However, the Framingham Heart Study did not find any association between CV risk and variation in
PRL levels (when within the reference range) [135]. Furthermore, differences in PRL values have not
been shown between women with different levels of CV risk [132].
Higher concentrations of several cardiac risk markers including total cholesterol, LDL, apo B,
platelet count, fibrinogen, AT-III, PAI-1 and PAI-1/t-PA have been reported in patients with
prolactinoma [136]. In a retrospective cohort study including 2233 individuals with prolactinoma
and 10,355 matched controls, only males were at increased risk of incident cardiovascular disease
(incidence rate ratio 1.94; 95% CI: 1.29–2.91, p = 0.001) [137]. However, the contribution of possible
growth hormone deficiency and/or hypogonadism in these findings cannot be excluded.
7. Hyperprolactinaemia and Autoimmunity
PRL modulates humoral and cellular immune responses through different but not completely
understood mechanisms. It induces production of IL-1, IL-6, and interferon γ, and expression of IL-2
receptors, regulates the maturation of CD4+ and CD8+ T-cell, modulates cytokine production, stimulates
pro-B cell generation, and reduces the apoptosis of transitional B cells [138,139]. Hyperprolactinaemia is
associated with enhanced activation of anergic B cells that promote autoreactivity [138,139]. Moreover,
pro-inflammatory cytokines stimulate pituitary PRL secretion [140] and lymphocytes express dopamine
receptors (predominantly D4R and D5R) modulating local PRL production and secretion [8]. A recent
case control study by Liu et al. [141] of 202 patients with hyperprolactinaemia found that a significantly
higher proportion of hyperprolactinaemic patients had at least one detectable autoantibody, as well as
higher levels of IL-4 and IL-6 compared to healthy controls.
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7.1. Lupus
A systematic review and meta-analysis of 12 studies by Wang et al. demonstrated significantly
higher PRL levels in patients with systematic lupus erythematosus (SLE) [142]. It should be noted
though that an association between hyperprolactinaemia and SLE has not been confirmed in all
reports [143]; in the systematic review by Wang et al. [142], differences in PRL levels between patients
and controls were statistically significant in populations from Asia and Europe but not from America.
Animal studies have found enhanced expression of PRL-R on T-cells, and that metoclopramide-
related hyperprolactinaemia induced features of SLE [144,145]. Human studies have also demonstrated
an association between hyperprolactinaemia and manifestations of lupus; hyperprolactinaemia in
patients with SLE has been associated with higher risk of serositis and anaemia [139], as well as with
neurological manifestations, renal involvement, haematological manifestations, and serological disease
markers, namely complement and anti-dsDNA [146].
7.2. Rheumatoid Arthritis
Studies on PRL levels in RA have provided inconsistent results with lower, higher, or equivocal
values [139,147]. It has been shown that the risk and severity of RA are decreased in reproductive
states characterized by hyperprolactinaemia (pregnancy and breastfeeding) [148]. However, others
have demonstrated that severe disease is associated with longer period of breast-feeding and larger
number of breastfed children [149]. A randomized placebo controlled study of bromocriptine offered
in 88 patients with active RA on background treatment with methotrexate did not have any significant
impact on disease activity score at three months [150].
Various hypotheses have been proposed for the inconsistent findings. It has been postulated that
lower PRL levels are immunostimulatory, whereas higher ones are immunosuppressive [148]. Others
have suggested that extra-pituitary PRL is more important in the pathogenesis of RA than pituitary
PRL; PRL-receptors have been demonstrated in synovial macrophages, and PRL mRNA expression in
synovial tissue is positively correlated with clinical disease activity [147,151]. Further reports have
also implicated the significance of extra-pituitary prolactin promoter polymorphisms [152].
7.3. Multiple Sclerosis
PRL has been implicated in the pathogenesis of multiple sclerosis (MS) and other demyelinating
disorders [149,153]. PRL is thought to have dual effect in the central nervous system; it stimulates
regeneration of neurons, oligodendrocytes, and neural stem cells, and also promotes aberrant immune
responses through stimulating B cell autoreactivity [149]. The latter mechanism possibly explains
the correlation between hyperprolactinaemia and MS [140,149]. Patients with MS have higher PRL
levels compared to controls, and this has also been shown in patients with neuromyelitis optica
(NMO) [140,153]. Notably, PRL is higher in patients with MS or NMO during attacks compared with
phases of remission [153] but it is still unclear whether hyperprolactinaemia is a primary cause or a
secondary effect of the disease.
7.4. Other Autoimmune Disorders
Hyperprolactinaemia has been described in numerous other autoimmune disorders including
systemic sclerosis, Behçet’s disease, and polymyositis [138]. In coeliac disease, a positive correlation
between serum PRL with disease activity, mucosal atrophy, and concentration of anti-endomysial
antibodies has been shown [149]. A small study demonstrated higher levels of the PRL-R in patients
with alopecia areata compared to controls, and levels of the PRL-R were correlated with disease
severity [154]. Patients with pemphigus vulgaris have also been shown to have higher PRL compared
with controls [155]. The pathophysiological significance of these findings remains to be elucidated.
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8. Cancer
An association with PRL levels and breast [156–158], ovarian [159], colon [160,161] and
hepatocellular [162] cancer has been suggested. Although basic science studies have implicated
a role for PRL and its receptor in the pathogenesis of different malignancies [157,158,163–166], a clear
causal relationship between PRL and cancer remains controversial [158]. Epidemiological studies on
this topic have shown conflicting results [158], and reports suggesting positive association between
PRL values and cancer risk should be interpreted with caution, as some include individuals with
normal PRL values, or rely on a single measurement of the hormone [156–158]. Notably, a study of
1342 women with hyperprolactinaemia treated with DA did not demonstrate increased risk of breast
cancer compared with the general population [167]. Well-designed epidemiological and clinical studies
are required to investigate reliably this issue.
9. Conclusions
Hyperprolactinaemia is a biochemical diagnosis with a broad range of aetiologies. Detailed history
and clinical assessment are important first steps for the differential diagnosis and for verification of
pathological causes. Exclusion of macroprolactin and consideration of the “hook effect” are important
points in the diagnostic approach. Medications and sellar/parasellar masses (prolactin secreting or
acting through the “stalk effect”) are the most common causes of pathological hyperprolactinaemia.
Treatment of hyperprolactinaemia mainly aims at restoration and maintenance of normal gonadal
function/fertility, and prevention of osteoporosis. Specific management strategies depend on the
underlying cause. A particularly challenging scenario is drug-induced hyperprolactinaemia, especially
when this occurs in association with antipsychotics or other psychiatric medications, as the degree
of PRL elevation can be variable and discontinuing or changing the culprit medication may not
be safe. DA are the mainstay of therapy for prolactinomas and specific guidelines are available in
clinical practice.
Recent data expand the biological effects of prolactin particularly on metabolism, cancer,
cardiovascular and immune systems opening new avenues on the clinical implications of prolactin
and the consequences of hyperprolactinaemia.
Author Contributions: I.S., K.L., and N.K. contributed to the literature review and the preparation of the
manuscript. N.K. supervised this work.
Funding: No funding to disclose.
Conflicts of Interest: The authors declare no conflicts of interest.
References
1. Tucker, H.A. Hormones, mammary growth, and lactation: A 41-year perspective. J. Dairy Sci. 2000, 83,
874–884. [CrossRef]
2. Trott, J.F.; Vonderhaar, B.K.; Hovey, R.C. Historical perspectives of prolactin and growth hormone as
mammogens, lactogens and galactagogues—Agog for the future! J. Mammary Gland Biol. Neoplasia 2008, 13,
3–11. [CrossRef] [PubMed]
3. Riddle, O.; Bates, R.W.; Dykshorn, S.W. The preparation, identification and assay of prolactin—A hormone
of the anterior pituitary. Am. J. Physiol. Leg. Content 1933, 105, 191–216. [CrossRef]
4. Friesen, H.; Guyda, H.; Hardy, J. Biosynthesis of Human Growth Hormone and Prolactin. J. Clin. Endocrinol.
Metab. 1970, 31, 611–624. [CrossRef]
5. Lewis, U.J.; Singh, R.N.; Seavey, B.K. Human prolactin: Isolation and some properties. Biochem. Biophys. Res.
Commun. 1971, 44, 1169–1176. [CrossRef]
6. Prabhakar, V.K.; Davis, J.R. Hyperprolactinaemia. Best Pract. Res. Clin. Obs. Gynaecol. 2008, 22, 341–353.
[CrossRef]
7. Teilum, K.; Hoch, J.C.; Goffin, V.; Kinet, S.; Martial, J.A.; Kragelund, B.B. Solution structure of human
prolactin. J. Mol. Biol. 2005, 351, 810–823. [CrossRef]
J. Clin. Med. 2019, 8, 2203 17 of 24
8. Freeman, M.E.; Kanyicska, B.; Lerant, A.; Nagy, G. Prolactin: Structure, function, and regulation of secretion.
Physiol. Rev. 2000, 80, 1523–1631. [CrossRef]
9. Capozzi, A.; Scambia, G.; Pontecorvi, A.; Lello, S. Hyperprolactinemia: Pathophysiology and therapeutic
approach. Gynecol. Endocrinol. 2015, 31, 506–510. [CrossRef]
10. Rastrelli, G.; Corona, G.; Maggi, M. The role of prolactin in andrology: What is new? Rev. Endocr. Metab.
Disord. 2015, 16, 233–248. [CrossRef]
11. Grattan, D.R. 60 YEARS OF NEUROENDOCRINOLOGY: The hypothalamo-prolactin axis. J. Endocrinol.
2015, 226, T101–T122. [CrossRef]
12. Cabrera-Reyes, E.A.; Limón-Morales, O.; Rivero-Segura, N.A.; Camacho-Arroyo, I.; Cerbón, M. Prolactin
function and putative expression in the brain. Endocrine 2017, 57, 199–213. [CrossRef]
13. Marano, R.J.; Ben-Jonathan, N. Minireview: Extrapituitary Prolactin: An Update on the Distribution,
Regulation, and Functions. Mol. Endocrinol. 2014, 28, 622–633. [CrossRef] [PubMed]
14. Ignacak, A.; Kasztelnik, M.; Sliwa, T.; Korbut, R.A.; Rajda, K.; Guzik, T.J. Prolactin–not only lactotrophin.
A “new” view of the “old” hormone. J. Physiol. Pharm. 2012, 63, 435–443.
15. Levine, S.; Muneyyirci-Delale, O. Stress-Induced Hyperprolactinemia: Pathophysiology and Clinical
Approach. Obs. Gynecol. Int. 2018, 2018, 9253083. [CrossRef]
16. Zaidi, M.; Sun, L.; Liu, P.; Davies, T.F.; New, M.; Zallone, A.; Yuen, T. Pituitary-bone connection in skeletal
regulation. Horm. Mol. Biol. Clin. Investig. 2016, 28, 85–94. [CrossRef]
17. Gregg, C.; Shikar, V.; Larsen, P.; Mak, G.; Chojnacki, A.; Yong, V.W.; Weiss, S. White matter plasticity and
enhanced remyelination in the maternal CNS. J. Neurosci. 2007, 27, 1812–1823. [CrossRef]
18. Tanner, M.J.; Hadlow, N.C.; Wardrop, R. Variation of female prolactin levels with menopausal status and
phase of menstrual cycle. Aust. N. Z. J. Obs. Gynaecol. 2011, 51, 321–324. [CrossRef]
19. Hu, Y.; Ding, Y.; Yang, M.; Xiang, Z. Serum prolactin levels across pregnancy and the establishment of
reference intervals. Clin. Chem. Lab. Med. 2018, 56, 803–807. [CrossRef]
20. Alvarez-Tutor, E.; Forga-LLenas, L.; Rodriguez-Erdozain, R.; Goñi-Iriarte, M.J.; Mendendez-Torre, E.;
Alvarez-Tutor, J. Persistent increase of PRL after oral contraceptive treatment. Alterations in dopaminergic
regulation as possible etiology. Arch. Gynecol. Obs. 1999, 263, 45–50. [CrossRef]
21. Banaszewska, B.; Pawelczyk, L.; Spaczynski, R.Z.; Dziura, J.; Duleba, A.J. Effects of simvastatin and oral
contraceptive agent on polycystic ovary syndrome: Prospective, randomized, crossover trial. J. Clin.
Endocrinol. Metab. 2007, 92, 456–461. [CrossRef] [PubMed]
22. Crowley, W.R. Neuroendocrine regulation of lactation and milk production. Compr. Physiol. 2015, 5, 255–291.
[CrossRef] [PubMed]
23. Muneyyirci-Delale, O.; Goldstein, D.; Reyes, F.I. Diagnosis of stress-related hyperprolactinemia. Evaluation
of the hyperprolactinemia rest test. N. Y. State J. Med. 1989, 89, 205–208. [PubMed]
24. Hackney, A.C.; Davis, H.C.; Lane, A.R. Growth Hormone-Insulin-Like Growth Factor Axis, Thyroid Axis,
Prolactin, and Exercise. Front. Horm. Res. 2016, 47, 1–11. [CrossRef] [PubMed]
25. Melmed, S.; Casanueva, F.F.; Hoffman, A.R.; Kleinberg, D.L.; Montori, V.M.; Schlechte, J.A.; Wass, J.A.;
Society, E. Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline.
J. Clin. Endocrinol. Metab. 2011, 96, 273–288. [CrossRef]
26. Vilar, L.; Fleseriu, M.; Bronstein, M.D. Challenges and pitfalls in the diagnosis of hyperprolactinemia.
Arq. Bras. Endocrinol. Metab. 2014, 58, 9–22. [CrossRef]
27. Saraç, F.; Tütüncüog˘lu, P.; Ozgen, A.G.; Saygili, F.; Yilmaz, C.; Bilgen, I.; Memis¸, A. Prolactin levels and
examination with breast ultrasound or mammography. Adv. Ther. 2008, 25, 59–66. [CrossRef]
28. Jarrell, J.; Franks, S.; McInnes, R.; Gemayel, K.; Guyda, H.; Arronet, G.H.; Naftolin, F. Breast examination
does not elevate serum prolactin. Fertil. Steril. 1980, 33, 49–51. [CrossRef]
29. Hammond, K.R.; Steinkampf, M.P.; Boots, L.R.; Blackwell, R.E. The effect of routine breast examination on
serum prolactin levels. Fertil. Steril. 1996, 65, 869–870. [CrossRef]
30. Fernandez, A.; Karavitaki, N.; Wass, J.A. Prevalence of pituitary adenomas: A community-based,
cross-sectional study in Banbury (Oxfordshire, UK). Clin. Endocrinol. Oxf. 2010, 72, 377–382. [CrossRef]
31. Maiter, D.; Delgrange, E. Therapy of endocrine disease: The challenges in managing giant prolactinomas.
Eur. J. Endocrinol. 2014, 170, R213–R227. [CrossRef] [PubMed]
J. Clin. Med. 2019, 8, 2203 18 of 24
32. Vilar, L.; Freitas, M.C.; Naves, L.A.; Casulari, L.A.; Azevedo, M.; Montenegro, R.; Barros, A.I.; Faria, M.;
Nascimento, G.C.; Lima, J.G.; et al. Diagnosis and management of hyperprolactinemia: Results of a Brazilian
multicenter study with 1234 patients. J. Endocrinol. Investig. 2008, 31, 436–444. [CrossRef] [PubMed]
33. Vilar, L.; Vilar, C.F.; Lyra, R.; Lyra, R.; Naves, L.A. Acromegaly: Clinical features at diagnosis. Pituitary 2017,
20, 22–32. [CrossRef] [PubMed]
34. Katznelson, L.; Laws, E.R., Jr.; Melmed, S.; Molitch, M.E.; Murad, M.H.; Utz, A.; Wass, J.A.; Endocrine, S.
Acromegaly: An endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2014, 99, 3933–3951.
[CrossRef]
35. Mete, O.; Lopes, M.B. Overview of the 2017 WHO Classification of Pituitary Tumors. Endocr. Pathol. 2017, 28,
228–243. [CrossRef]
36. Schernthaner-Reiter, M.H.; Trivellin, G.; Stratakis, C.A. MEN1, MEN4, and Carney Complex: Pathology and
Molecular Genetics. Neuroendocrinology 2016, 103, 18–31. [CrossRef]
37. Thakker, R.V. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol. Cell. Endocrinol. 2014,
386, 2–15. [CrossRef]
38. Agarwal, S.K.; Ozawa, A.; Mateo, C.M.; Marx, S.J. The MEN1 gene and pituitary tumours. Horm. Res. 2009,
71 (Suppl. S2), 131–138. [CrossRef]
39. Beckers, A.; Aaltonen, L.A.; Daly, A.F.; Karhu, A. Familial isolated pituitary adenomas (FIPA) and the
pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein
(AIP) gene. Endocr. Rev. 2013, 34, 239–277. [CrossRef]
40. Kurtkaya-Yapicier, O.; Scheithauer, B.W.; Carney, J.A.; Kovacs, K.; Horvath, E.; Stratakis, C.A.; Vidal, S.;
Vella, A.; Young, W.F.; Atkinson, J.L.; et al. Pituitary adenoma in Carney complex: An immunohistochemical,
ultrastructural, and immunoelectron microscopic study. Ultrastruct. Pathol. 2002, 26, 345–353. [CrossRef]
41. Sun, F.; Sun, X.; Du, X.; Xing, H.; Yang, B. Factors related to endocrine changes and hormone substitution
treatment during pre- and post-operation stages in craniopharyngioma. Oncol. Lett. 2017, 13, 250–252.
[CrossRef] [PubMed]
42. Karavitaki, N.; Thanabalasingham, G.; Shore, H.C.; Trifanescu, R.; Ansorge, O.; Meston, N.; Turner, H.E.;
Wass, J.A. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study
of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin. Endocrinol. Oxf.
2006, 65, 524–529. [CrossRef] [PubMed]
43. Vilar, L.; Abucham, J.; Albuquerque, J.L.; Araujo, L.A.; Azevedo, M.F.; Boguszewski, C.L.; Casulari, L.A.;
Cunha Neto, M.B.C.; Czepielewski, M.A.; Duarte, F.H.G.; et al. Controversial issues in the management
of hyperprolactinemia and prolactinomas—An overview by the Neuroendocrinology Department of the
Brazilian Society of Endocrinology and Metabolism. Arch. Endocrinol. Metab. 2018, 62, 236–263. [CrossRef]
[PubMed]
44. Chiloiro, S.; Giampietro, A.; Bianchi, A.; Tartaglione, T.; Capobianco, A.; Anile, C.; De Marinis, L. Diagnosis
of endocrine disease: Primary empty sella: A comprehensive review. Eur. J. Endocrinol. 2017, 177, R275–R285.
[CrossRef]
45. Lo, J.C.; Beck, G.J.; Kaysen, G.A.; Chan, C.T.; Kliger, A.S.; Rocco, M.V.; Chertow, G.M.; Study, F.
Hyperprolactinemia in end-stage renal disease and effects of frequent hemodialysis. Hemodial. Int. 2017,
21, 190–196. [CrossRef] [PubMed]
46. Balakrishnan, C.H.; Rajeev, H. Correlation of Serum Prolactin Level to Child Pugh Scoring System in Cirrhosis
of Liver. J. Clin. Diagn. Res. 2017, 11, OC30–OC33. [CrossRef]
47. Sharma, L.K.; Sharma, N.; Gadpayle, A.K.; Dutta, D. Prevalence and predictors of hyperprolactinemia in
subclinical hypothyroidism. Eur. J. Intern. Med. 2016, 35, 106–110. [CrossRef]
48. Honbo, K.S.; van Herle, A.J.; Kellett, K.A. Serum prolactin levels in untreated primary hypothyroidism.
Am. J. Med. 1978, 64, 782–787. [CrossRef]
49. Shivaprasad, K.S.; Siddardha, K. Pituitary Hyperplasia from Primary Hypothyroidism. N. Engl. J. Med. 2019,
380, e9. [CrossRef]
50. Kyritsi, E.M.; Dimitriadis, G.K.; Angelousi, A.; Mehta, H.; Shad, A.; Mytilinaiou, M.; Kaltsas, G.; Randeva, H.S.
The value of prolactin in predicting prolactinoma in hyperprolactinaemic polycystic ovarian syndrome.
Eur. J. Clin. Investig. 2018, 48, e12961. [CrossRef]
51. Kyritsi, E.M.; Dimitriadis, G.K.; Kyrou, I.; Kaltsas, G.; Randeva, H.S. PCOS remains a diagnosis of exclusion:
A concise review of key endocrinopathies to exclude. Clin. Endocrinol. Oxf. 2017, 86, 1–6. [CrossRef]
J. Clin. Med. 2019, 8, 2203 19 of 24
52. Filho, R.B.; Domingues, L.; Naves, L.; Ferraz, E.; Alves, A.; Casulari, L.A. Polycystic ovary syndrome and
hyperprolactinemia are distinct entities. Gynecol. Endocrinol. 2007, 23, 267–272. [CrossRef]
53. Nass, R.D.; Sassen, R.; Elger, C.E.; Surges, R. The role of postictal laboratory blood analyses in the diagnosis
and prognosis of seizures. Seizure 2017, 47, 51–65. [CrossRef]
54. Lusic´, I.; Pintaric´, I.; Hozo, I.; Boic´, L.; Capkun, V. Serum prolactin levels after seizure and syncopal attacks.
Seizure 1999, 8, 218–222. [CrossRef]
55. Peuskens, J.; Pani, L.; Detraux, J.; De Hert, M. The effects of novel and newly approved antipsychotics on
serum prolactin levels: A comprehensive review. CNS Drugs 2014, 28, 421–453. [CrossRef]
56. Montejo, Á.; Arango, C.; Bernardo, M.; Carrasco, J.L.; Crespo-Facorro, B.; Cruz, J.J.; Del Pino, J.; García
Escudero, M.A.; García Rizo, C.; González-Pinto, A.; et al. Spanish consensus on the risks and detection of
antipsychotic drug-related hyperprolactinaemia. Rev. Psiquiatr. Salud Ment. 2016, 9, 158–173. [CrossRef]
57. Cortet-Rudelli, C.; Sapin, R.; Bonneville, J.F.; Brue, T. Etiological diagnosis of hyperprolactinemia.
Ann. Endocrinol. Paris 2007, 68, 98–105. [CrossRef]
58. Molitch, M.E. Medication-induced hyperprolactinemia. Mayo Clin. Proc. 2005, 80, 1050–1057. [CrossRef]
59. Ajmal, A.; Joffe, H.; Nachtigall, L.B. Psychotropic-induced hyperprolactinemia: A clinical review.
Psychosomatics 2014, 55, 29–36. [CrossRef]
60. Tewksbury, A.; Olander, A. Management of antipsychotic-induced hyperprolactinemia. Ment. Health Clin.
2016, 6, 185–190. [CrossRef]
61. Reeves, S.; Sugita, E.; Baldeweg, S.E.; Howard, R. Management of antipsychotic related hyperprolactinemia
in older people: Can we extrapolate from existing guidance? Int. J. Geriatr. Psychiatry 2018, 33, 1743–1744.
[CrossRef]
62. McMurdo, M.E.; Howie, P.W.; Lewis, M.; Marnie, M.; McEwen, J.; McNeilly, A.S. Prolactin response to low
dose sulpiride. Br. J. Clin. Pharm. 1987, 24, 133–137. [CrossRef]
63. Cookson, J.; Hodgson, R.; Wildgust, H.J. Prolactin, hyperprolactinaemia and antipsychotic treatment:
A review and lessons for treatment of early psychosis. J. Psychopharmacol. 2012, 26, 42–51. [CrossRef]
64. Ingram, J.; Taylor, H.; Churchill, C.; Pike, A.; Greenwood, R. Metoclopramide or domperidone for increasing
maternal breast milk output: A randomised controlled trial. Arch. Dis. Child. Fetal Neonatal Ed. 2012, 97,
F241–F245. [CrossRef]
65. Fountas, A.; Chai, S.T.; Kourkouti, C.; Karavitaki, N. Mechanisms of endocrinology: Endocrinology of
opioids. Eur. J. Endocrinol. 2018, 179, R183–R196. [CrossRef]
66. Romeo, J.H.; Dombrowski, R.; Kwak, Y.S.; Fuehrer, S.; Aron, D.C. Hyperprolactinaemia and verapamil:
Prevalence and potential association with hypogonadism in men. Clin. Endocrinol. Oxf. 1996, 45, 571–575.
[CrossRef]
67. Kelley, S.R.; Kamal, T.J.; Molitch, M.E. Mechanism of verapamil calcium channel blockade-induced
hyperprolactinemia. Am. J. Physiol. 1996, 270, E96–E100. [CrossRef]
68. Veselinovic´, T.; Schorn, H.; Vernaleken, I.B.; Schiﬄ, K.; Klomp, M.; Gründer, G. Impact of different
antidopaminergic mechanisms on the dopaminergic control of prolactin secretion. J. Clin. Psychopharmacol.
2011, 31, 214–220. [CrossRef]
69. Kleinberg, D.L.; Noel, G.L.; Frantz, A.G. Galactorrhea: A study of 235 cases, including 48 with pituitary
tumors. N. Engl. J. Med. 1977, 296, 589–600. [CrossRef]
70. Finken, M.J.; Boersma, B.; Rotteveel, J. Hyperprolactinemia and hyperandrogenism in an adolescent girl
presenting with primary amenorrhea. Eur. J. Obs. Gynecol. Reprod. Biol. 2013, 166, 230–231. [CrossRef]
71. Majumdar, A.; Mangal, N.S. Hyperprolactinemia. J. Hum. Reprod. Sci. 2013, 6, 168–175. [CrossRef]
72. Moria, Y.; Kortbawi, R.; El-Asmar, N.; Arafah, B.M. Increased androgen secretion in patients with
prolactinomas: The impact of altered HPA function. Pituitary 2019, 22, 170–178. [CrossRef]
73. Carmina, E.; Azziz, R.; Bergfeld, W.; Escobar Morreale, H.F.; Futterweit, W.; Huddleston, H.; Lobo, R.A.;
Olsen, E. Female pattern hair loss and androgen excess: A report from the multidisciplinary androgen excess
and pcos committee. J. Clin. Endocrinol. Metab. 2019, 104, 2875–2891. [CrossRef]
74. Serri, O.; Chik, C.L.; Ur, E.; Ezzat, S. Diagnosis and management of hyperprolactinemia. Can. Med. Assoc. J.
2003, 169, 575–581.
75. De Rosa, M.; Zarrilli, S.; Di Sarno, A.; Milano, N.; Gaccione, M.; Boggia, B.; Lombardi, G.; Colao, A.
Hyperprolactinemia in men: Clinical and biochemical features and response to treatment. Endocrine 2003, 20,
75–82. [CrossRef]
J. Clin. Med. 2019, 8, 2203 20 of 24
76. Tirosh, A.; Benbassat, C.; Lifshitz, A.; Shimon, I. Hypopituitarism patterns and prevalence among men with
macroprolactinomas. Pituitary 2015, 18, 108–115. [CrossRef]
77. Mazziotti, G.; Frara, S.; Giustina, A. Pituitary Diseases and Bone. Endocr. Rev. 2018, 39, 440–488. [CrossRef]
78. Ozer, F.F.; Dagdelen, S.; Erbas, T. Relation of RANKL and OPG Levels with Bone Resorption in Patients with
Acromegaly and Prolactinoma. Horm. Metab. Res. 2018, 50, 562–567. [CrossRef]
79. Di Somma, C.; Colao, A.; Di Sarno, A.; Klain, M.; Landi, M.L.; Facciolli, G.; Pivonello, R.; Panza, N.;
Salvatore, M.; Lombardi, G. Bone marker and bone density responses to dopamine agonist therapy in
hyperprolactinemic males. J. Clin. Endocrinol. Metab. 1998, 83, 807–813. [CrossRef]
80. Mazziotti, G.; Mancini, T.; Mormando, M.; De Menis, E.; Bianchi, A.; Doga, M.; Porcelli, T.; Vescovi, P.P.;
De Marinis, L.; Giustina, A. High prevalence of radiological vertebral fractures in women with
prolactin-secreting pituitary adenomas. Pituitary 2011, 14, 299–306. [CrossRef]
81. D’Sylva, C.; Khan, T.; Van Uum, S.; Fraser, L.A. Osteoporotic fractures in patients with untreated
hyperprolactinemia vs. those taking dopamine agonists: A systematic review and meta-analysis.
Neuro Endocrinol. Lett. 2015, 36, 745–749.
82. Casanueva, F.F.; Molitch, M.E.; Schlechte, J.A.; Abs, R.; Bonert, V.; Bronstein, M.D.; Brue, T.; Cappabianca, P.;
Colao, A.; Fahlbusch, R.; et al. Guidelines of the Pituitary Society for the diagnosis and management of
prolactinomas. Clin. Endocrinol. Oxf. 2006, 65, 265–273. [CrossRef]
83. Saleem, M.; Martin, H.; Coates, P. Prolactin Biology and Laboratory Measurement: An Update on Physiology
and Current Analytical Issues. Clin. Biochem. Rev. 2018, 39, 3–16.
84. Lippi, G.; Plebani, M. Macroprolactin: Searching for a needle in a haystack? Clin. Chem. Lab. Med. 2016, 54,
519–522. [CrossRef]
85. Samson, S.L.; Hamrahian, A.H.; Ezzat, S.; Aace, N.; Pituitary Scientific Committee. American association of
clinical endocrinologists, American college of endocrinology disease state clinical review: Clinical relevance
of macroprolactin in the absence or presence of true hyperprolactinemia. Endocr. Pract. 2015, 21, 1427–1435.
[CrossRef]
86. Kasum, M.; Oreškovic´, S.; Cˇehic´, E.; Šunj, M.; Lila, A.; Ejubovic´, E. Laboratory and clinical significance
of macroprolactinemia in women with hyperprolactinemia. Taiwan J. Obs. Gynecol. 2017, 56, 719–724.
[CrossRef]
87. Kalsi, A.K.; Halder, A.; Jain, M.; Chaturvedi, P.K.; Sharma, J.B. Prevalence and reproductive manifestations
of macroprolactinemia. Endocrine 2019, 63, 332–340. [CrossRef]
88. Romijn, J.A. Hyperprolactinemia and prolactinoma. Handb. Clin. Neurol. 2014, 124, 185–195. [CrossRef]
89. Grigg, J.; Worsley, R.; Thew, C.; Gurvich, C.; Thomas, N.; Kulkarni, J. Antipsychotic-induced
hyperprolactinemia: Synthesis of world-wide guidelines and integrated recommendations for assessment,
management and future research. Psychopharmacology 2017, 234, 3279–3297. [CrossRef]
90. Santharam, S.; Fountas, A.; Tampourlou, M.; Arlt, W.; Ayuk, J.; Gittoes, N.; Toogood, A.; Karavitaki, N. Impact
of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal. Clin. Endocrinol.
Oxf. 2018, 89, 346–353. [CrossRef]
91. Iacovazzo, D.; De Marinis, L. Treatment of hyperprolactinemia in post-menopausal women: Pros. Endocrine
2015, 48, 76–78. [CrossRef]
92. Liu, X.; Tang, C.; Wen, G.; Zhong, C.; Yang, J.; Zhu, J.; Ma, C. The Mechanism and Pathways of Dopamine
and Dopamine Agonists in Prolactinomas. Front. Endocrinol. Lausanne 2018, 9, 768. [CrossRef] [PubMed]
93. Barlier, A.; Jaquet, P. Quinagolide—A valuable treatment option for hyperprolactinaemia. Eur. J. Endocrinol.
2006, 154, 187–195. [CrossRef] [PubMed]
94. Colao, A.; Di Sarno, A.; Guerra, E.; De Leo, M.; Mentone, A.; Lombardi, G. Drug insight: Cabergoline and
bromocriptine in the treatment of hyperprolactinemia in men and women. Nat. Clin. Pract. Endocrinol.
Metab. 2006, 2, 200–210. [CrossRef] [PubMed]
95. Schade, R.; Andersohn, F.; Suissa, S.; Haverkamp, W.; Garbe, E. Dopamine agonists and the risk of
cardiac-valve regurgitation. N. Engl. J. Med. 2007, 356, 29–38. [CrossRef] [PubMed]
96. Stiles, C.E.; Tetteh-Wayoe, E.T.; Bestwick, J.; Steeds, R.P.; Drake, W.M. A meta-analysis of the prevalence of
cardiac valvulopathy in hyperprolactinemic patients treated with Cabergoline. J. Clin. Endocrinol. Metab.
2018. [CrossRef]
97. Auriemma, R.S.; Pivonello, R.; Ferreri, L.; Priscitelli, P.; Colao, A. Cabergoline use for pituitary tumors and
valvular disorders. Endocrinol. Metab. Clin. N. Am. 2015, 44, 89–97. [CrossRef]
J. Clin. Med. 2019, 8, 2203 21 of 24
98. Vroonen, L.; Lancellotti, P.; Garcia, M.T.; Dulgheru, R.; Rubio-Almanza, M.; Maiga, I.; Magne, J.; Petrossians, P.;
Auriemma, R.; Daly, A.F.; et al. Prospective, long-term study of the effect of cabergoline on valvular status in
patients with prolactinoma and idiopathic hyperprolactinemia. Endocrine 2017, 55, 239–245. [CrossRef]
99. Gamble, D.; Fairley, R.; Harvey, R.; Farman, C.; Cantley, N.; Leslie, S.J. Screening for valve disease in patients
with hyperprolactinaemia disorders prescribed cabergoline: A service evaluation and literature review.
Adv. Drug Saf. 2017, 8, 215–229. [CrossRef]
100. Steeds, R.P.; Stiles, C.E.; Sharma, V.; Chambers, J.B.; Lloyd, G.; Drake, W. Echocardiography and monitoring
patients receiving dopamine agonist therapy for hyperprolactinaemia: A joint position statement of the
British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology.
Echo Res. Pract. 2019, 6, G1–G8. [CrossRef]
101. Gillam, M.P.; Molitch, M.E.; Lombardi, G.; Colao, A. Advances in the treatment of prolactinomas. Endocr. Rev.
2006, 27, 485–534. [CrossRef]
102. Noronha, S.; Stokes, V.; Karavitaki, N.; Grossman, A. Treating prolactinomas with dopamine agonists:
Always worth the gamble? Endocrine 2016, 51, 205–210. [CrossRef] [PubMed]
103. Chng, E.; Dalan, R. Pituitary apoplexy associated with cabergoline therapy. J. Clin. Neurosci. 2013, 20,
1637–1643. [CrossRef]
104. Ghadirian, H.; Shirani, M.; Ghazi-Mirsaeed, S.; Mohebi, S.; Alimohamadi, M. Pituitary Apoplexy during
Treatment of Prolactinoma with Cabergoline. Asian J. Neurosurg. 2018, 13, 93–95. [CrossRef] [PubMed]
105. Glezer, A.; Bronstein, M.D. Pituitary apoplexy: Pathophysiology, diagnosis and management. Arch. Endocrinol.
Metab. 2015, 59, 259–264. [CrossRef] [PubMed]
106. Huang, W.; Molitch, M.E. Pituitary Tumors in Pregnancy. Endocrinol. Metab. Clin. N. Am. 2019, 48, 569–581.
[CrossRef]
107. Auriemma, R.S.; Perone, Y.; Di Sarno, A.; Grasso, L.F.; Guerra, E.; Gasperi, M.; Pivonello, R.; Colao, A. Results
of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy
and lactation. J. Clin. Endocrinol. Metab. 2013, 98, 372–379. [CrossRef]
108. Domingue, M.E.; Devuyst, F.; Alexopoulou, O.; Corvilain, B.; Maiter, D. Outcome of prolactinoma after
pregnancy and lactation: A study on 73 patients. Clin. Endocrinol. Oxf. 2014, 80, 642–648. [CrossRef]
109. Souteiro, P.; Karavitaki, N. Dopamine agonist resistant prolactinomas: Any alternative medical treatment?
Pituitary 2019, 1–11. [CrossRef]
110. Maiter, D. Management of Dopamine Agonist-Resistant Prolactinoma. Neuroendocrinology 2019, 109, 42–50.
[CrossRef]
111. Molitch, M.E. Management of medically refractory prolactinoma. J. Neurooncol. 2014, 117, 421–428. [CrossRef]
112. Raverot, G.; Burman, P.; McCormack, A.I.; Heaney, A.P.; Petersenn, S.; Popovic, V.; Trouillas, J.; Dekkers, O.
European Society of Endocrinology clinical practice guidelines for the management of aggressive pituitary
tumours and carcinomas. Eur. J. Endocrinol. 2017, 178, G1–G24. [CrossRef] [PubMed]
113. Nakhleh, A.; Shehadeh, N.; Hochberg, I.; Zloczower, M.; Zolotov, S.; Taher, R.; Daoud Naccache, D.
Management of cystic prolactinomas: A review. Pituitary 2018, 21, 425–430. [CrossRef] [PubMed]
114. Tampourlou, M.; Trifanescu, R.; Paluzzi, A.; Ahmed, S.K.; Karavitaki, N. Therapy of endocrine disease:
Surgery in microprolactinomas: Effectiveness and risks based on contemporary literature. Eur. J. Endocrinol.
2016, 175, R89–R96. [CrossRef] [PubMed]
115. Colao, A. Pituitary tumours: The prolactinoma. Best Pract. Res. Clin. Endocrinol. Metab. 2009, 23, 575–596.
[CrossRef] [PubMed]
116. Han, Y.L.; Chen, D.M.; Zhang, C.; Pan, M.; Yang, X.P.; Wu, Y.G. Retrospective analysis of 52 patients with
prolactinomas following endoscopic endonasal transsphenoidal surgery. Med. Baltim. 2018, 97, e13198.
[CrossRef]
117. Ntali, G.; Karavitaki, N. Efficacy and complications of pituitary irradiation. Endocrinol. Metab. Clin. N. Am.
2015, 44, 117–126. [CrossRef]
118. Pereira, A.M.; Romijn, J.A.; Dekkers, O.M. Treatment and Follow-Up of Clinically Nonfunctioning Pituitary
Macroadenomas. J. Clin. Endocrinol. Metab. 2008, 93, 3717–3726. [CrossRef]
119. Zaidi, H.A.; Cote, D.J.; Castlen, J.P.; Burke, W.T.; Liu, Y.H.; Smith, T.R.; Laws, E.R. Time Course of Resolution
of Hyperprolactinemia After Transsphenoidal Surgery Among Patients Presenting with Pituitary Stalk
Compression. World Neurosurg. 2017, 97, 2–7. [CrossRef]
J. Clin. Med. 2019, 8, 2203 22 of 24
120. Huang, W.; Molitch, M.E. Evaluation and management of galactorrhea. Am. Fam. Physician 2012, 85,
1073–1080.
121. Greenman, Y.; Cooper, O.; Yaish, I.; Robenshtok, E.; Sagiv, N.; Jonas-Kimchi, T.; Yuan, X.; Gertych, A.;
Shimon, I.; Ram, Z.; et al. Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists.
Eur. J. Endocrinol. 2016, 175, 63–72. [CrossRef]
122. Ben-Jonathan, N.; Hugo, E. Prolactin (PRL) in adipose tissue: Regulation and functions. Adv. Exp. Med. Biol.
2015, 846, 1–35. [CrossRef] [PubMed]
123. Carré, N.; Binart, N. Prolactin and adipose tissue. Biochimie 2014, 97, 16–21. [CrossRef] [PubMed]
124. Wang, T.; Lu, J.; Xu, Y.; Li, M.; Sun, J.; Zhang, J.; Xu, B.; Xu, M.; Chen, Y.; Bi, Y.; et al. Circulating prolactin
associates with diabetes and impaired glucose regulation: A population-based study. Diabetes Care 2013, 36,
1974–1980. [CrossRef] [PubMed]
125. Li, J.; Rice, M.S.; Huang, T.; Hankinson, S.E.; Clevenger, C.V.; Hu, F.B.; Tworoger, S.S. Circulating prolactin
concentrations and risk of type 2 diabetes in US women. Diabetologia 2018, 61, 2549–2560. [CrossRef]
126. Atmaca, A.; Bilgici, B.; Ecemis, G.C.; Tuncel, O.K. Evaluation of body weight, insulin resistance, leptin
and adiponectin levels in premenopausal women with hyperprolactinemia. Endocrine 2013, 44, 756–761.
[CrossRef]
127. Dos Santos Silva, C.M.; Barbosa, F.R.; Lima, G.A.; Warszawski, L.; Fontes, R.; Domingues, R.C.; Gadelha, M.R.
BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists.
Obes. Silver Spring 2011, 19, 800–805. [CrossRef]
128. Schwetz, V.; Librizzi, R.; Trummer, C.; Theiler, G.; Stiegler, C.; Pieber, T.R.; Obermayer-Pietsch, B.; Pilz, S.
Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas.
Metab. Brain Dis. 2017, 32, 155–161. [CrossRef]
129. Medic-Stojanoska, M.; Icin, T.; Pletikosic, I.; Bajkin, I.; Novakovic-Paro, J.; Stokic, E.; Spasic, D.T.;
Kovacev-Zavisic, B.; Abenavoli, L. Risk factors for accelerated atherosclerosis in young women with
hyperprolactinemia. Med. Hypotheses 2015, 84, 321–326. [CrossRef]
130. Auriemma, R.S.; Granieri, L.; Galdiero, M.; Simeoli, C.; Perone, Y.; Vitale, P.; Pivonello, C.; Negri, M.;
Mannarino, T.; Giordano, C.; et al. Effect of cabergoline on metabolism in prolactinomas. Neuroendocrinology
2013, 98, 299–310. [CrossRef]
131. Auriemma, R.S.; Galdiero, M.; Vitale, P.; Granieri, L.; Lo Calzo, F.; Salzano, C.; Ferreri, L.; Pivonello, C.;
Cariati, F.; Coppola, G.; et al. Effect of chronic cabergoline treatment and testosterone replacement on
metabolism in male patients with prolactinomas. Neuroendocrinology 2015, 101, 66–81. [CrossRef]
132. Ozdemir, E.D.; Caglar, G.S.; Akgul, E.; Cengiz, S.D.; Tombak, G. The association between prolactin,
high-sensitivity C-reactive protein and Framingham risk score in menopause. Gynecol. Obs. Investig. 2014,
78, 119–123. [CrossRef] [PubMed]
133. Fleseriu, M.; Hashim, I.A.; Karavitaki, N.; Melmed, S.; Murad, M.H.; Salvatori, R.; Samuels, M.H. Hormonal
Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. J. Clin.
Endocrinol. Metab. 2016, 101, 3888–3921. [CrossRef] [PubMed]
134. Zhang, L.; Curhan, G.C.; Forman, J.P. Plasma prolactin level and risk of incident hypertension in
postmenopausal women. J. Hypertens. 2010, 28, 1400–1405. [CrossRef] [PubMed]
135. Therkelsen, K.E.; Abraham, T.M.; Pedley, A.; Massaro, J.M.; Sutherland, P.; Hoffmann, U.; Fox, C.S. Association
Between Prolactin and Incidence of Cardiovascular Risk Factors in the Framingham Heart Study. J. Am.
Heart Assoc. 2016, 5. [CrossRef] [PubMed]
136. Erem, C.; Kocak, M.; Nuhoglu, I.; Yılmaz, M.; Ucuncu, O. Blood coagulation, fibrinolysis and lipid profile in
patients with prolactinoma. Clin. Endocrinol. Oxf. 2010, 73, 502–507. [CrossRef]
137. Toulis, K.A.; Robbins, T.; Reddy, N.; Balachandran, K.; Gokhale, K.; Wijesinghe, H.; Cheng, K.K.; Karavitaki, N.;
Wass, J.; Nirantharakumar, K. Males with prolactinoma are at increased risk of incident cardiovascular
disease. Clin. Endocrinol. Oxf. 2018, 88, 71–76. [CrossRef]
138. Shelly, S.; Boaz, M.; Orbach, H. Prolactin and autoimmunity. Autoimmun. Rev. 2012, 11, A465–A470.
[CrossRef]
139. Orbach, H.; Zandman-Goddard, G.; Boaz, M.; Agmon-Levin, N.; Amital, H.; Szekanecz, Z.; Szucs, G.;
Rovensky, J.; Kiss, E.; Doria, A.; et al. Prolactin and autoimmunity: Hyperprolactinemia correlates with
serositis and anemia in SLE patients. Clin. Rev. Allergy Immunol. 2012, 42, 189–198. [CrossRef]
J. Clin. Med. 2019, 8, 2203 23 of 24
140. Correale, J.; Farez, M.F.; Ysrraelit, M.C. Role of prolactin in B cell regulation in multiple sclerosis.
J. Neuroimmunol. 2014, 269, 76–86. [CrossRef]
141. Liu, Y.; Zhang, Z.; Jin, Q.; Kang, Z.; Huo, Y.; He, Z.; Feng, X.; Yin, J.; Wu, X.; Wang, H.; et al. Hyperprolactinemia
is associated with a high prevalence of serum autoantibodies, high levels of inflammatory cytokines and an
abnormal distribution of peripheral B-cell subsets. Endocrine 2019, 64, 648–656. [CrossRef]
142. Wang, P.; Lv, T.T.; Guan, S.Y.; Li, H.M.; Leng, R.X.; Zou, Y.F.; Pan, H.F. Increased plasma/serum levels of
prolactin in systemic lupus erythematosus: A systematic review and meta-analysis. Postgrad. Med. 2017, 129,
126–132. [CrossRef] [PubMed]
143. Aulestia, C.; De Zubiría, A.; Granados, C.; Suárez, J.; Cervera, R. Prolactin and Estradiol Profile in a Cohort
of Colombian Women with Systemic Lupus Erythematosus. Isr. Med. Assoc. J. 2016, 18, 537–541. [PubMed]
144. Ledesma-Soto, Y.; Blanco-Favela, F.; Fuentes-Pananá, E.M.; Tesoro-Cruz, E.; Hernández-González, R.;
Arriaga-Pizano, L.; Legorreta-Haquet, M.V.; Montoya-Diaz, E.; Chávez-Sánchez, L.; Castro-Mussot, M.E.;
et al. Increased levels of prolactin receptor expression correlate with the early onset of lupus symptoms and
increased numbers of transitional-1 B cells after prolactin treatment. BMC Immunol. 2012, 13, 11. [CrossRef]
[PubMed]
145. Savino, W. Prolactin: An Immunomodulator in Health and Disease. Front. Horm. Res. 2017, 48, 69–75.
[CrossRef] [PubMed]
146. Leaños-Miranda, A.; Cárdenas-Mondragón, G. Serum free prolactin concentrations in patients with systemic
lupus erythematosus are associated with lupus activity. Rheumatol. Oxf. 2006, 45, 97–101. [CrossRef]
147. Tang, M.W.; Garcia, S.; Gerlag, D.M.; Tak, P.P.; Reedquist, K.A. Insight into the Endocrine System and the
Immune System: A Review of the Inflammatory Role of Prolactin in Rheumatoid Arthritis and Psoriatic
Arthritis. Front. Immunol. 2017, 8, 720. [CrossRef]
148. Clapp, C.; Adán, N.; Ledesma-Colunga, M.G.; Solís-Gutiérrez, M.; Triebel, J.; Martínez de la Escalera, G.
The role of the prolactin/vasoinhibin axis in rheumatoid arthritis: An integrative overview. Cell. Mol. Life Sci.
2016, 73, 2929–2948. [CrossRef]
149. Borba, V.V.; Zandman-Goddard, G.; Shoenfeld, Y. Prolactin and Autoimmunity. Front. Immunol. 2018, 9, 73.
[CrossRef]
150. Salesi, M.; Sadeghihaddadzavareh, S.; Nasri, P.; Namdarigharaghani, N.; Farajzadegan, Z.; Hajalikhani, M.
The role of bromocriptine in the treatment of patients with active rheumatoid arthritis. Int. J. Rheum. Dis.
2013, 16, 662–666. [CrossRef]
151. Tang, M.W.; Garcia, S.; Malvar Fernandez, B.; Gerlag, D.M.; Tak, P.P.; Reedquist, K.A. Rheumatoid arthritis
and psoriatic arthritis synovial fluids stimulate prolactin production by macrophages. J. Leukoc. Biol. 2017,
102, 897–904. [CrossRef]
152. Reyes-Castillo, Z.; Pereira-Suárez, A.L.; Palafox-Sanchez, C.A.; Rangel-Villalobos, H.; Estrada-Chávez, C.;
Oregón-Romero, E.; Angel-Chávez, L.I.; Muñoz-Barrios, S.; Bueno-Topete, M.R.; Muñoz-Valle, J.F.
The extrapituitary prolactin promoter polymorphism is associated with rheumatoid arthritis and anti-CCP
antibodies in Mexican population. Gene 2013, 525, 130–135. [CrossRef] [PubMed]
153. Türkog˘lu, R.; Giris¸, M.; Gencer, M.; Akcan, U.; Örçen, A. Serum Prolactin Levels in Multiple Sclerosis,
Neuromyelitis Optica, and Clinically Isolated Syndrome Patients. Noro Psikiyatr. Arsivi 2016, 53, 353–356.
[CrossRef] [PubMed]
154. El Tahlawi, S.M.; El Eishi, N.H.; Kahhal, R.K.; Hegazy, R.A.; El Hanafy, G.M.; Abdel Hay, R.M.; Shaker, O.G.
Do Prolactin and its Receptor Play a Role in Alopecia Areata? Indian J. Derm. 2018, 63, 241–245. [CrossRef]
[PubMed]
155. Lajevardi, V.; Hallaji, Z.; Daneshpazhooh, M.; Ghandi, N.; Shekari, P.; Khani, S. Evaluation of prolactin levels
in patients with newly diagnosed pemphigus vulgaris and its correlation with pemphigus disease area index.
Int. J. Womens Derm. 2016, 2, 53–55. [CrossRef]
156. Tworoger, S.S.; Hankinson, S.E. Prolactin and breast cancer etiology: An epidemiologic perspective.
J. Mammary Gland Biol. Neoplasia 2008, 13, 41–53. [CrossRef]
157. Tworoger, S.S.; Eliassen, A.H.; Zhang, X.; Qian, J.; Sluss, P.M.; Rosner, B.A.; Hankinson, S.E. A 20-year
prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res. 2013, 73,
4810–4819. [CrossRef]
158. Bernard, V.; Young, J.; Chanson, P.; Binart, N. New insights in prolactin: Pathological implications. Nat. Rev.
Endocrinol. 2015, 11, 265–275. [CrossRef]
J. Clin. Med. 2019, 8, 2203 24 of 24
159. Clendenen, T.V.; Arslan, A.A.; Lokshin, A.E.; Liu, M.; Lundin, E.; Koenig, K.L.; Berrino, F.; Hallmans, G.;
Idahl, A.; Krogh, V.; et al. Circulating prolactin levels and risk of epithelial ovarian cancer. Cancer Causes
Control 2013, 24, 741–748. [CrossRef]
160. Ilan, Y.; Sibirsky, O.; Livni, N.; Gofrit, O.; Barack, V.; Goldin, E. Plasma and tumor prolactin in colorectal
cancer patients. Dig. Dis. Sci. 1995, 40, 2010–2015. [CrossRef]
161. Bhatavdekar, J.M.; Patel, D.D.; Giri, D.D.; Karelia, N.H.; Vora, H.H.; Ghosh, N.; Shah, N.G.; Trivedi, S.N.;
Balar, D.B. Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon
and rectum. Br. J. Cancer 1992, 66, 977–980. [CrossRef]
162. Yeh, Y.T.; Lee, K.T.; Tsai, C.J.; Chen, Y.J.; Wang, S.N. Prolactin promotes hepatocellular carcinoma through
Janus kinase 2. World J. Surg. 2012, 36, 1128–1135. [CrossRef] [PubMed]
163. Yonezawa, T.; Chen, K.H.; Ghosh, M.K.; Rivera, L.; Dill, R.; Ma, L.; Villa, P.A.; Kawaminami, M.; Walker, A.M.
Anti-metastatic outcome of isoform-specific prolactin receptor targeting in breast cancer. Cancer Lett. 2015,
366, 84–92. [CrossRef] [PubMed]
164. Goffin, V. Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge.
Pharm. Ther. 2017, 179, 111–126. [CrossRef] [PubMed]
165. Ding, K.; Yuan, Y.; Chong, Q.Y.; Yang, Y.; Li, R.; Li, X.; Kong, X.; Qian, P.; Xiong, Z.; Pandey, V.; et al.
Autocrine Prolactin Stimulates Endometrial Carcinoma Growth and Metastasis and Reduces Sensitivity to
Chemotherapy. Endocrinology 2017, 158, 1595–1611. [CrossRef] [PubMed]
166. Neradugomma, N.K.; Subramaniam, D.; Tawfik, O.W.; Goffin, V.; Kumar, T.R.; Jensen, R.A.; Anant, S.
Prolactin signaling enhances colon cancer stemness by modulating Notch signaling in a Jak2-STAT3/ERK
manner. Carcinogenesis 2014, 35, 795–806. [CrossRef] [PubMed]
167. Dekkers, O.M.; Romijn, J.A.; de Boer, A.; Vandenbroucke, J.P. The risk for breast cancer is not evidently
increased in women with hyperprolactinemia. Pituitary 2010, 13, 195–198. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
